|
1
|
Garciaz S, Coso D, Brice P and Bouabdallah
R: Hodgkin and non-Hodgkin lymphoma of adolescents and young
adults. Bull Cancer. 103:1035–1049. 2016.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vega GG, Avilés-Salas A, Chalapud JR,
Martinez-Paniagua M, Pelayo R, Mayani H, Hernandez-Pando R,
Martinez-Maza O, Huerta-Yepez S, Bonavida B and Vega MI: P38 MAPK
expression and activation predicts failure of response to CHOP in
patients with diffuse large B-cell lymphoma. BMC Cancer.
15:7222015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang J, Wei B, Hu H, Liu F, Tu Y, Zhao M
and Wu D: Preliminary study on decreasing the expression of FOXP3
with miR-155 to inhibit diffuse large B-cell lymphoma. Oncol Lett.
14:1711–1718. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hu X, Zeng M, Yang SE, Liang X, Ding SS,
Guo L, Li S and Wen SJ: Efficacy of rituximab combined with CHOP
for treating patients with diffuse large B-cell lymphoma. Medicine
(Baltimore). 96:e84942017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
De Paepe P, Achten R, Verhoef G, Wlodarska
I, Stul M, Vanhentenrijk V, Praet M and De Wolf-Peeters C: Large
cleaved and immunoblastic lymphoma may represent two distinct
clinicopathologic entities within the group of diffuse large B-cell
lymphomas. J Clin Oncol. 23:7060–7068. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tumwine LK, Agostinelli C, Campidelli C,
Othieno E, Wabinga H, Righi S, Falini B, Piccaluga PP, Byarugaba W
and Pileri SA: Immnohistochemical and other prognostic factors in B
cell non Hodgkin lymphoma patients, Kampala, Uganda. BMC Clin
Pathol. 9:112009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Offner F, Samoilova O, Osmanov E, Eom HS,
Topp MS, Raposo J, Pavlov V, Ricci D, Chaturvedi S, Zhu E, et al:
Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone
with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.
Blood. 126:1893–1901. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Leonard JP, Kolibaba KS, Reeves JA,
Tulpule A, Flinn IW, Kolevska T, Robles R, Flowers CR, Collons R,
DiBella NJ, et al: Randomized phase II study of R-CHOP with or
without bortezomib in previously untreated patients with
non-germinal center B-cell-like diffuse large B-cell lymphoma. J
Clin Oncol. 35:3538–3546. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Murthy SL, Hitchcock MA, Endicott-Yazdani
TR, Watson JT and Krause JR: Epstein-barr virus-positive diffuse
large B-cell lymphoma. Proc (Bayl Univ Med Cent). 30:443–444. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
van Krieken JH: New developments in the
pathology of malignant lymphoma: A review of the literature
published from May to August 2017. J Hematop. 10:65–73. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bognar MK, Vincendeau M, Erdmann T,
Seeholzer T, Grau M, Linnemann JR, Ruland J, Scheel CH, Lenz P, Ott
G, et al: Oncogenic CARMA1 couples NF-κB and β-catenin signaling in
diffuse large B-cell lymphomas. Oncogene. 35:4269–4281. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Young RM, Shaffer AL III, Phelan JD and
Staudt LM: B cell receptor signaling in diffuse large B cell
lymphoma. Semin Hematol. 52:77–85. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao Y, Gou WF, Chen S, Takano Y, Xiu YL
and Zheng HC: BTG1 expression correlates with the pathogenesis and
progression of ovarian carcinomas. Int J Mol Sci. 14:19670–19680.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rouault JP, Rimokh R, Tessa C, Paranhos G,
Ffrench M, Duret L, Garoccio M, Germain D, Samarut J and Magaud JP:
BTG1, a member of a new family of antiproliferative genes. EMBO J.
11:1663–1670. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mauxion F, Chen CY, Séraphin B and Shyu
AB: BTG/TOB factors impact deadenylases. Trends Biochem Sci.
34:640–647. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Busson M, Carazo A, Seyer P, Grandemange
S, Casas F, Pessemesse L, Rouault JP, Wrutniak-Cabello C and
Cabello G: Coactivation of nuclear receptors and myogenic factors
induces the major BTG1 influence on muscle differentiation.
Oncogene. 24:1698–1710. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yin P, Song G and Jiang Z: Cisplatin
suppresses proliferation, migration and invasion of nasopharyngeal
carcinoma cells in vitro by repressing the
Wnt/β-catenin/Endothelin-1 axis via activating B cell translocation
gene 1. Cancer Chemother Pharmacol. 81:863–872. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rouaul JP, Prévôt D, Berthet C, Birot AM,
Billaud M, Magaud JP and Corbo L: Interaction of BTG1 and
p53-regulated BTG2 gene products with mCaf1, the murine homolog of
a component of the yeast CCR4 transcriptional regulatory complex. J
Biol Chem. 273:22563–22569. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tijchon E, van Emst L, Yuniati L, van
lngen Schenau D, Gerritsen M, van der Meer LT, Williams O,
Hoogerbrugge PM, Scheijen B and van Leeuwen FN: Tumor suppressor
BTG1 limits activation of BCL6 expression downstream of ETV6-RUNX1.
Exp Hematol. 60:57–62.e3. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu C, Tao T, Xu B, Lu K, Zhang L, Jiang
L, Chen S, Liu D, Zhang X, Cao N and Chen M: BTG1 potentiates
apoptosis and suppresses proliferation in renal cell carcinoma by
interacting with PRMT1. Oncol Lett. 10:619–624. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
He C, Yu T, Shi Y, Ma C, Yang W, Fang L,
Sun M, Wu W, Xiao F, Guo F, et al: MicroRNA 301A promotes
intestinal inflammation and colitis-associated cancer development
by inhibiting BTG1. Gastroenterology. 152:1434–1448.e15. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Corjay MH, Kearney MA, Mnzer DA, Diamond
SM and Stoltenborg JK: Antiproliferative gene BTG1 is highly
expressed in apoptotic cells in macrophage-rich areas of advanced
lesions in Watanabe heritable hyperlipidemic rabbit and human. Lab
Invest. 78:847–858. 1998.PubMed/NCBI
|
|
23
|
Scheijen B, Boer JM, Marke R, Tijchon E,
van lngen Schenau D, Waanders E, van Emst L, van der Meer LT,
Pieters R, Escherich G, et al: Tumor suppressors BTG1 and IKZF1
cooperate during mouse leukemia development and increase relapse
risk in B-cell precursor acute lymphoblastic leukemia patients.
Haematologica. 102:541–551. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tijchon E, van Emst L, Yuniati L, van
lngen Schenau D, Havinga J, Rouault JP, Hoogerbrugge PM, van
Leeuwen FN and Scheijen B: Tumor suppressors BTG1 and BTG2 regulate
early mouse B-cell development. Haematologica. 101:e272–e276. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Visco C, Li Y, Xu-Monette ZY, Miranda RN,
Green TM, Li Y, Tzankov A, Wen W, Liu WM, Kahl BS, et al:
Comprehensive gene expression profiling and immunohistochemical
studies support application of immunophenotypic algorithm for
molecular subtype classification in diffuse large B-cell lymphoma:
A report from the International DLBCL Rituximab-CHOP consortium
program study. Leukemia. 26:2103–2113. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Simon R, Durrleman S, Hoppe RT, Bonadonna
G, Bloomfield CD, Rudders RA, Cheaon BD and Berard CW: The
non-hodgkin lymphoma pthologic classification profect. Long-term
follow-up of 1153 patients with non-Hodgkin lymphomas. Ann Intern
Med. 109:939–945. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Meyer PN, Fu K, Greiner TC, Smith LM,
Delabie J, Gascoyne RD, Ott G, Rosenwald A, Braziel RM, Campo E, et
al: Immunohistochemical methods for predicting cell of origin and
survival in patients with diffuse large B-cell lymphoma treated
with rituximab. J Clin Oncol. 29:200–207. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dubois S and Jardin F: Novel molecular
classifications of DLBCL. Nat Rev Clin Oncol. 15:474–476. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liao YX, Zhang ZP, Zhao J and Liu JP:
Effects of fibronectin 1 on cell proliferation, senescence and
apoptosis of human glioma cells through the PI3K/AKT signaling
pathway. Cell Physiol Biochem. 48:1382–1396. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zang Y, Gu L, Zhang Y, Wang Y and Xue F:
Identification of key genes and pathways in uterine leiomyosarcoma
through bioinformatics analysis. Oncol Lett. 15:9361–9368.
2018.PubMed/NCBI
|
|
31
|
Rosenwald A, Wright G, Chan WC, Connors
JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland
EB, Giltnane JM, et al: The use of molecular profiling to predict
survival after chemotherapy for diffuse large-B-cell lymphoma. N
Engl J Med. 346:1937–1947. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pan Y, Lu L, Chen J, Zhong Y and Dai Z:
Identification of potential crucial genes and construction of
microRNA-mRNA negative regulatory network in osteosarcoma.
Hereditas. 155:212018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen W, Zheng R, Zeng H and Zhang S: The
incidence and mortality of major cancers in China, 2012. Chin J
Cancer. 35:732016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu J, Song Y, Su L, Xu L, Chen T, Zhao Z,
Zhang M, Li W, Hu Y, Zhang X, et al: Rituximab plus chemotherapy as
first-line treatment in Chinese patients with diffuse large B-cell
lymphoma in routine practice: A prospective, multicentre,
non-interventional study. BMC Cancer. 16:5372016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yamauchi T, Tasaki T, Tai K, Ikegaya S,
Takagi K, Negoro E, Kishi S, Yoshida A, Iwasaki H and Ueda T:
Prognostic effect of peripheral blood cell counts in advanced
diffuse large B-cell lymphoma treated with R-CHOP-like
chemotherapy: A single institution analysis. Oncol Lett. 9:851–856.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Huang Y, Zheng J, Tan T, Song L, Huang S,
Zhang Y, Lin L, Liu J, Zheng P, Chen X, et al: BTG1 low expression
in pancreatic ductal adenocarcinoma is associated with a poorer
prognosis. Int J Biol Markers. 33:189–194. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rimokh R, Rouault JP, Wahbi K, Gadoux M,
Lafage M, Archimbaud E, Charrin C, Gentilhomme O, Germain D,
Samarut J, et al: A chromosome 12 coding region is juxtaposed to
the MYC protooncogene locus in a t(8;12)(q24;q22) translocation in
a case of B-cell chronic lymphocytic leukemia. Genes Chromosomes
Cancer. 3:24–36. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhao S, Chen SR, Yang XF, Shen DF, Takano
Y, Su RJ and Zheng HC: BTG1 might be employed as a biomarker for
carcinogenesis and a target for gene therapy in colorectal cancers.
Oncotarget. 8:7502–7520. 2017.PubMed/NCBI
|
|
39
|
Zhou X, Liao WJ, Liao JM, Liao P and Lu H:
Ribosomal proteins: Functions beyond the ribosome. J Mol Cell Biol.
7:92–104. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen YC, Chang MY, Shiau AL, Yo YT and Wu
CL: Mitochondrial ribosomal protein S36 delays cell cycle
progression in association with p53 modification and p21(WAF1/CIP1)
expression. J Cell Biochem. 100:981–190. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lohrum MA, Ludwig RL, Kubbutat MH, Hanlon
M and Vousden KH: Regulation of HDM2 activity by the ribosomal
protein L11. Cancer Cell. 3:577–587. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dai MS and Lu H: Inhibition of
MDM2-mediated p53 ubiquitination and degradation by ribosomal
protein L5. J Biol Chem. 279:44475–44482. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Daftular L, Zhu Y, Jacq X and Prives C:
Ribosomal proteins RPL37, RPS15 and RPS20 regulate the
Mdm2-p53-MdmX network. PLoS One. 8:e686672013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhou X, Hao Q, Liao J, Zhang Q and Lu H:
Ribosomal protein S14 unties the MDM2-p53 loop upon ribosomal
stress. Oncogene. 32:388–396. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Challagundla KB, Sun XX, Zhang X, DeVine
T, Zhang Q, Sears RC and Dai MS: Ribosomal protein L11 recruits
miR-24/miRISC to repress c-Myc expression in response to ribosomal
stress. Mol Cell Biol. 31:4007–4021. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
De Keesmaecker K, Atak ZK, Li N, Vicente
C, Patchett S, Girardi T, Gianfelici V, Geerdens E, Clappier E,
Porcu M, et al: Exome sequencing identifies mutation in CNOT3 and
ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic
leukemia. Nat Genet. 45:186–190. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mao J, O'Gorman C, Sutovsky M, Zigo M,
Wells KD and Sutovsky P: Ubiquitin A-52 residue ribosomal protein
fusion product 1 (Uba52) is essential for preimplantation embryo
development. Biol Open. 7(pii): bio035717. 2018.
|
|
48
|
Kobayashi M, Oshima S, Maeyashiki C, Nibe
Y, Otsubo K, Matsuzawa Y, Nemoto Y, Nagaishi T, Okamoto R, Tsuchiya
K, et al: The ubiquitin hybrid gene UBA52 regulates ubiquitination
of ribosome and sustains embryonic development. Sci Rep.
6:367802016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Gregorj C, Ricciardi MR, Petrucci MT,
Scerpa MC, De Cave F, Fazi P, Vignetti M, Vitale A, Mancini M,
Cimino G, et al: ERK1/2 phosphorylation is an independent predictor
of complete remission in newly diagnosed adult acute lymphoblastic
leukemia. Blood. 109:5473–5476. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Farhan M, Wang H, Gaur U, Little PJ, Xu J
and Zheng W: FOXO signaling pathways as therapeutic targets in
cancer. Int J Biol Sci. 13:815–827. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhou H and Huang S: mTOR signaling in
cancer cell motility and tumor metastasis. Crit Rev Eukaryot Gene
Expr. 20:1–16. 2010. View Article : Google Scholar : PubMed/NCBI
|
